Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 134

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus aureus

Lade, Harshad, Kim, Jae-Seok·2021·Antibiotics
DOI 10.3390/antibiotics10040398
Open this paper in CoChat — free account

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most prevalent bacterial pathogens and continues to be a leading cause of morbidity and mortality worldwide. MRSA is a commensal bacterium in humans and is transmitted in both community and healthcare settings. Successful treatment remains a challenge, and a search for new targets of antibiotics is required to ensure that MRSA infections can be effectively treated in the future. Most antibiotics in clinical use selectively target one or more biochemical processes essential for S. aureus viability, e.g., cell wall synthesis, protein synthesis (translation), DNA replication, RNA synthesis (transcription), or metabolic processes, such as folic acid synthesis. In this review, we briefly describe the mechanism of action of antibiotics from different classes and discuss insights into the well-established primary targets in S. aureus. Further, several components of bacterial cellular processes, such as teichoic acid, aminoacyl-tRNA synthetases, the lipid II cycle, auxiliary factors of β-lactam resistance, two-component systems, and the accessory gene regulator quorum sensing system, are discussed as promising targets for novel antibiotics. A greater molecular understanding of the bacterial targets of antibiotics has the potential to reveal novel therapeutic strategies or identify agents against antibiotic-resistant pathogens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antibiotics10040398

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 256

  1. Blair, 2015, Molecular mechanisms of antibiotic resistance, Nat. Rev. Microbiol., 13, 42, 10.1038/nrmicro3380 · DOI · Paper page
  2. Yin, 2003, Transcriptional Induction of the Penicillin-Binding Protein 2 Gene in Staphylococcus aureus by Cell Wall-Active Antibiotics Oxacillin and Vancomycin, Antimicrob. Agents Chemother., 47, 1028, 10.1128/AAC.47.3.1028-1036.2003 · doi:10.1128/aac.47.3.1028-1036.2003
  3. Zeng, 2016, Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance, Cold Spring Harb. Perspect. Med., 6, a026989, 10.1101/cshperspect.a026989 · DOI · Paper page
  4. Swaney, 1998, The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria, Antimicrob. Agents Chemother., 42, 3251, 10.1128/AAC.42.12.3251 · DOI · Paper page
  5. Kisgen, 2014, Tedizolid: A new oxazolidinone antimicrobial, Am. J. Health Pharm., 71, 621, 10.2146/ajhp130482 · DOI
  6. Champney, 1995, Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus, Antimicrob. Agents Chemother., 39, 2141, 10.1128/AAC.39.9.2141 · DOI
  7. Drlica, 1999, Mechanism of fluoroquinolone action, Curr. Opin. Microbiol., 2, 504, 10.1016/S1369-5274(99)00008-9 · DOI
  8. Drlica, 2008, Quinolone-Mediated Bacterial Death, Antimicrob. Agents Chemother., 52, 385, 10.1128/AAC.01617-06 · DOI · Paper page
  9. Calvori, 1965, Effect of Rifamycin on Protein Synthesis, Nature, 207, 417, 10.1038/207417a0 · DOI · Paper page
  10. Hitchings, 1973, Mechanism of Action of Trimethoprim-Sulfamethoxazole—I, J. Infect. Dis., 128, S433, 10.1093/infdis/128.Supplement_3.S433 · doi:10.1093/infdis/128.supplement_3.s433
  11. Grim, 2005, Trimethoprim-Sulfamethoxazole as a Viable Treatment Option for Infections Caused by Methicillin-Resistant Staphylococcus aureus, Pharmacotherapy, 25, 253, 10.1592/phco.25.2.253.56956 · DOI
  12. Rayner, 2005, Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus, Intern. Med. J., 35, S3, 10.1111/j.1444-0903.2005.00976.x · DOI · Paper page
  13. Lee, 2018, Methicillin-resistant Staphylococcus aureus, Nat. Rev. Dis. Prim., 4, 18033, 10.1038/nrdp.2018.33 · DOI · Paper page
  14. Turner, 2019, Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research, Nat. Rev. Microbiol., 17, 203, 10.1038/s41579-018-0147-4 · DOI · Paper page
  15. Lowy, 1998, Staphylococcus aureus Infections, N. Engl. J. Med., 339, 520, 10.1056/NEJM199808203390806 · DOI · Paper page
  16. Tong, 2015, Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management, Clin. Microbiol. Rev., 28, 603, 10.1128/CMR.00134-14 · DOI · Paper page
  17. Balasubramanian, 2017, Staphylococcus aureus pathogenesis in diverse host environments, Pathog. Dis., 75, ftx005, 10.1093/femspd/ftx005 · DOI · Paper page
  18. Tsuzuki, 2020, National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan, J. Infect. Chemother., 26, 367, 10.1016/j.jiac.2019.10.017 · DOI
  19. Boucher, 2009, Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America, Clin. Infect. Dis., 48, 1, 10.1086/595011 · DOI · Paper page
  20. Peacock, 2015, Mechanisms of Methicillin Resistance in Staphylococcus aureus, Annu. Rev. Biochem., 84, 577, 10.1146/annurev-biochem-060614-034516 · DOI · Paper page
  21. Vestergaard, M., Frees, D., and Ingmer, H. (2019). Antibiotic Resistance and the MRSA Problem. Gram-Positive Pathogens, ASM Press. · DOI
  22. Jensen, 2009, Genetics of antimicrobial resistance in Staphylococcus aureus, Future Microbiol., 4, 565, 10.2217/fmb.09.30 · DOI · Paper page
  23. Ito, 1999, Cloning and Nucleotide Sequence Determination of the Entire mec DNA of Pre-Methicillin-Resistant Staphylococcus aureus N315, Antimicrob. Agents Chemother., 43, 1449, 10.1128/AAC.43.6.1449 · DOI · Paper page
  24. Jang, 2016, Multidrug efflux pumps in Staphylococcus aureus and their clinical implications, J. Microbiol., 54, 1, 10.1007/s12275-016-5159-z · DOI
  25. Foster, 2016, The remarkably multifunctional fibronectin binding proteins of Staphylococcus aureus, Eur. J. Clin. Microbiol. Infect. Dis., 35, 1923, 10.1007/s10096-016-2763-0 · DOI
  26. Hong, S.I., Lee, Y.-M., Park, K.-H., Ryu, B.-H., Hong, K.-W., Kim, S., Bae, I.-G., and Cho, O.-H. (2019). Clinical and Molecular Characteristics of qacA- and qacB-Positive Methicillin-Resistant Staphylococcus aureus Causing Bloodstream Infections. Antimicrob. Agents Chemother., 63. · doi:10.1128/aac.02157-18
  27. Malachowa, 2010, Mobile genetic elements of Staphylococcus aureus, Cell. Mol. Life Sci., 67, 3057, 10.1007/s00018-010-0389-4 · DOI · Paper page
  28. Lim, 2006, Prevalence of Inducible Clindamycin Resistance in Staphylococcal Isolates at a Korean Tertiary Care Hospital, Yonsei Med. J., 47, 480, 10.3349/ymj.2006.47.4.480 · doi:10.3349/ymj.2006.47.4.480
  29. Hartman, 1984, Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus, J. Bacteriol., 158, 513, 10.1128/jb.158.2.513-516.1984 · DOI · Paper page
  30. Fuda, 2005, β-Lactam resistance in Staphylococcus aureus: The adaptive resistance of a plastic genome, Cell. Mol. Life Sci., 62, 2617, 10.1007/s00018-005-5148-6 · DOI · Paper page
  31. Chambers, 1990, Binding of β-Lactam Antibiotics to Penicillin-Binding Proteins in Methicillin-Resistant Staphylococcus aureus, J. Infect. Dis., 161, 1170, 10.1093/infdis/161.6.1170 · DOI
  32. Kirby, 1944, Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci, Science, 99, 452, 10.1126/science.99.2579.452 · DOI · Paper page
  33. Fisher, J.F., and Mobashery, S. (2020). β-Lactams against the Fortress of the Gram-Positive Staphylococcus aureus Bacterium. Chem. Rev. · DOI
  34. Sauvage, 2008, The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis, FEMS Microbiol. Rev., 32, 234, 10.1111/j.1574-6976.2008.00105.x · DOI · Paper page
  35. Shalaby, 2020, Penicillin binding protein 2a: An overview and a medicinal chemistry perspective, Eur. J. Med. Chem., 199, 112312, 10.1016/j.ejmech.2020.112312 · DOI
  36. Tomasz, 1994, Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 38, 2590, 10.1128/AAC.38.11.2590 · DOI · Paper page
  37. Kayser, 1989, FemA, a host-mediated factor essential for methicillin resistance in Staphylococcus aureus: Molecular cloning and characterization, Mol. Gen. Genet. MGG, 219, 263, 10.1007/BF00261186 · DOI · Paper page
  38. Katayama, 2000, A New Class of Genetic Element, Staphylococcus Cassette Chromosome mec, Encodes Methicillin Resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 44, 1549, 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
  39. Matsuhashi, 1986, Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus, J. Bacteriol., 167, 975, 10.1128/jb.167.3.975-980.1986 · DOI · Paper page
  40. Lakhundi, S., and Zhang, K. (2018). Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin. Microbiol. Rev., 31. · DOI · Paper page
  41. Kim, 2012, Properties of a Novel PBP2A Protein Homolog from Staphylococcus aureus Strain LGA251 and Its Contribution to the β-Lactam-resistant Phenotype*, J. Biol. Chem., 287, 36854, 10.1074/jbc.M112.395962 · doi:10.1074/jbc.m112.395962
  42. Zhao, 1999, Penicillin-Binding Protein 2a of Streptococcus pneumoniae: Expression in Escherichia coli and Purification and Refolding of Inclusion Bodies into a Soluble and Enzymatically Active Enzyme, Protein Expr. Purif., 16, 331, 10.1006/prep.1999.1080 · doi:10.1006/prep.1999.1080
  43. Sanbongi, 2004, Complete Sequences of Six Penicillin-Binding Protein Genes from 40 Streptococcus pneumoniae Clinical Isolates Collected in Japan, Antimicrob. Agents Chemother., 48, 2244, 10.1128/AAC.48.6.2244-2250.2004 · DOI
  44. Zhao, 2000, Identification and Characterization of the Penicillin-Binding Protein 2a of Streptococcus pneumoniae and Its Possible Role in Resistance to β-Lactam Antibiotics, Antimicrob. Agents Chemother., 44, 1745, 10.1128/AAC.44.6.1745-1748.2000 · DOI
  45. Grebe, 1996, Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics, Antimicrob. Agents Chemother., 40, 829, 10.1128/AAC.40.4.829 · DOI · Paper page
  46. Lowy, 2003, Antimicrobial resistance: The example of Staphylococcus aureus, J. Clin. Investig., 111, 1265, 10.1172/JCI18535 · DOI · Paper page
  47. Maddux, 1991, Effects of ß-Lactamase-Mediated Antimicrobial Resistance: The Role of ß-Lactamase Inhibitors, Pharmacother. J. Hum. Pharmacol. Drug Ther., 11, 40S, 10.1002/j.1875-9114.1991.tb02618.x · doi:10.1002/j.1875-9114.1991.tb02618.x
  48. Tooke, 2019, β-Lactamases and β-Lactamase Inhibitors in the 21st Century, J. Mol. Biol., 431, 3472, 10.1016/j.jmb.2019.04.002 · DOI · Paper page
  49. Babic, 2006, What’s new in antibiotic resistance? Focus on beta-lactamases, Drug Resist. Updat., 9, 142, 10.1016/j.drup.2006.05.005 · DOI · Paper page
  50. Bush, K., and Bradford, P.A. (2020). Epidemiology of β-lactamase-producing pathogens. Clin. Microbiol. Rev., 33. · DOI · Paper page
  51. Bush, K. (2018). Past and present perspectives on β-lactamases. Antimicrob. Agents Chemother., 62. · DOI · Paper page
  52. Meini, 2019, AmpC β-lactamase-producing Enterobacterales: What a clinician should know, Infection, 47, 363, 10.1007/s15010-019-01291-9 · DOI · Paper page
  53. Kot, 2020, Antimicrobial Resistance Patterns in Methicillin-Resistant Staphylococcus aureus from Patients Hospitalized during 2015–2017 in Hospitals in Poland, Med. Princ. Pract., 29, 61, 10.1159/000501788 · doi:10.1159/000501788
  54. Rossato, 2020, Resistance profile to antimicrobials agents in methicillin-resistant Staphylococcus aureus isolated from hospitals in South Brazil between 2014–2019, Rev. Soc. Bras. Med. Trop., 53, e20200431, 10.1590/0037-8682-0431-2020 · DOI
  55. Weigel, 2003, Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus, Science, 302, 1569, 10.1126/science.1090956 · DOI · Paper page
  56. Mwangi, 2007, Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing, Proc. Natl. Acad. Sci. USA, 104, 9451, 10.1073/pnas.0609839104 · DOI · Paper page
  57. Chen, 2015, Multiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia, J. Antimicrob. Chemother., 70, 2965, 10.1093/jac/dkv225 · DOI
  58. Thitiananpakorn, 2020, Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA), Sci. Rep., 10, 16107, 10.1038/s41598-020-73108-x · DOI
  59. Bayer, 2016, Dysregulation of mprF and dltABCD expression among daptomycin-non-susceptible MRSA clinical isolates, J. Antimicrob. Chemother., 71, 2100, 10.1093/jac/dkw142 · doi:10.1093/jac/dkw142
  60. Dubrac, 2008, A matter of life and death: Cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway, Mol. Microbiol., 70, 1307, 10.1111/j.1365-2958.2008.06483.x · DOI · Paper page
  61. Jones, 2008, Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding, Antimicrob. Agents Chemother., 52, 269, 10.1128/AAC.00719-07 · DOI · Paper page
  62. Yang, 2010, Cell Wall Thickening Is Not a Universal Accompaniment of the Daptomycin Nonsusceptibility Phenotype in Staphylococcus aureus: Evidence for Multiple Resistance Mechanisms, Antimicrob. Agents Chemother., 54, 3079, 10.1128/AAC.00122-10 · DOI
  63. Arbeit, 2004, The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections, Clin. Infect. Dis., 38, 1673, 10.1086/420818 · DOI · Paper page
  64. Shorr, 2005, Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies, J. Antimicrob. Chemother., 56, 923, 10.1093/jac/dki355 · DOI · Paper page
  65. Weigelt, 2005, Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections, Antimicrob. Agents Chemother., 49, 2260, 10.1128/AAC.49.6.2260-2266.2005 · DOI · Paper page
  66. Fowler, 2006, Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus, N. Engl. J. Med., 355, 653, 10.1056/NEJMoa053783 · DOI · Paper page
  67. Goto, 2020, Trends of the Use of Anti-methicillin-Resistant Staphylococcus aureus Agents in Japan Based on Sales Data from 2006 to 2015, Biol. Pharm. Bull., 43, 1906, 10.1248/bpb.b20-00605 · DOI
  68. Tyers, 2019, Drug combinations: A strategy to extend the life of antibiotics in the 21st century, Nat. Rev. Microbiol., 17, 141, 10.1038/s41579-018-0141-x · DOI · Paper page
  69. Salam, 2018, Targeting Virulence in Staphylococcus aureus by Chemical Inhibition of the Accessory Gene Regulator System In Vivo, mSphere, 3, 1, 10.1128/mSphere.00500-17 · DOI
  70. Allen, 2014, Targeting virulence: Can we make evolution-proof drugs?, Nat. Rev. Microbiol., 12, 300, 10.1038/nrmicro3232 · DOI · Paper page
  71. Moller, A.G., Winston, K., Ji, S., Wang, J., Hargita Davis, M.N., Solís-Lemus, C.R., and Read, T.D. (2021). Genes Influencing Phage Host Range in Staphylococcus aureus on a Species-Wide Scale. mSphere, 6. · DOI
  72. Nobrega, 2015, Revisiting phage therapy: New applications for old resources, Trends Microbiol., 23, 185, 10.1016/j.tim.2015.01.006 · DOI · Paper page
  73. Gilmer, 2013, Novel Bacteriophage Lysin with Broad Lytic Activity Protects against Mixed Infection by Streptococcus pyogenes and Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 57, 2743, 10.1128/AAC.02526-12 · DOI · Paper page
  74. Lood, R., Molina, H., and Fischetti, V.A. (2017). Determining bacteriophage endopeptidase activity using either fluorophore-quencher labeled peptides combined with liquid chromatography-mass spectrometry (LC-MS) or Förster resonance energy transfer (FRET) assays. PLoS ONE, 12. · DOI
  75. Wright, 2010, Q&A: Antibiotic resistance: Where does it come from and what can we do about it?, BMC Biol., 8, 123, 10.1186/1741-7007-8-123 · DOI · Paper page
  76. Page, 2014, Penicillin-binding proteins: Evergreen drug targets, Curr. Opin. Pharmacol., 18, 112, 10.1016/j.coph.2014.09.012 · DOI
  77. Biedenbach, 2016, In vitro activity of ceftaroline against Staphylococcus aureus isolated in 2012 from Asia-Pacific countries as part of the AWARE surveillance program, Antimicrob. Agents Chemother., 60, 343, 10.1128/AAC.01867-15 · DOI
  78. McGhee, 2010, Affinity of Ceftaroline and Other -Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae, Antimicrob. Agents Chemother., 54, 1670, 10.1128/AAC.00019-10 · DOI · Paper page
  79. Moisan, 2010, Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae, J. Antimicrob. Chemother., 65, 713, 10.1093/jac/dkp503 · DOI
  80. Laudano, 2011, Ceftaroline fosamil: A new broad-spectrum cephalosporin, J. Antimicrob. Chemother., 66, iii11, 10.1093/jac/dkr095 · DOI
  81. Parenti, 1986, Structure and mechanism of action of teicoplanin, J. Hosp. Infect., 7, 79, 10.1016/0195-6701(86)90011-3 · DOI
  82. Grein, 2020, Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids, Nat. Commun., 11, 1455, 10.1038/s41467-020-15257-1 · DOI · Paper page
  83. Taylor, 2016, The action mechanism of daptomycin, Bioorg. Med. Chem., 24, 6253, 10.1016/j.bmc.2016.05.052 · DOI · Paper page
  84. Bayer, 2013, Mechanisms of daptomycin resistance in Staphylococcus aureus: Role of the cell membrane and cell wall, Ann. N. Y. Acad. Sci., 1277, 139, 10.1111/j.1749-6632.2012.06819.x · DOI · Paper page
  85. Muraih, 2011, Oligomerization of daptomycin on membranes, Biochim. Biophys. Acta—Biomembr., 1808, 1154, 10.1016/j.bbamem.2011.01.001 · DOI
  86. Silverman, 2003, Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus, Antimicrob. Agents Chemother., 47, 2538, 10.1128/AAC.47.8.2538-2544.2003 · DOI · Paper page
  87. Mascio, 2007, Bactericidal Action of Daptomycin against Stationary-Phase and Nondividing Staphylococcus aureus Cells, Antimicrob. Agents Chemother., 51, 4255, 10.1128/AAC.00824-07 · DOI · Paper page
  88. Allington, 2001, Quinupristin/dalfopristin: A therapeutic review, Clin. Ther., 23, 24, 10.1016/S0149-2918(01)80028-X · DOI
  89. Long, 2005, Agents for the treatment of multidrug-resistant gram-positive endocarditis, Curr. Infect. Dis. Rep., 7, 245, 10.1007/s11908-005-0055-4 · DOI
  90. Carter, 2000, Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics, Nature, 407, 340, 10.1038/35030019 · DOI · Paper page
  91. Magnet, 2005, Molecular Insights into Aminoglycoside Action and Resistance, Chem. Rev., 105, 477, 10.1021/cr0301088 · DOI · Paper page
  92. Matsumoto, 2014, Arbekacin: Another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens, Clin. Pharmacol. Adv. Appl., 6, 139
  93. Zhanel, 2015, Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens, Drugs, 75, 253, 10.1007/s40265-015-0352-7 · DOI · Paper page
  94. Ross, 1998, 16S rRNA Mutation Associated with Tetracycline Resistance in a Gram-Positive Bacterium, Antimicrob. Agents Chemother., 42, 1702, 10.1128/AAC.42.7.1702 · DOI · Paper page
  95. Geigenmuller, 1986, Tetracycline can inhibit tRNA binding to the ribosomal P site as well as to the A site, Eur. J. Biochem., 161, 723, 10.1111/j.1432-1033.1986.tb10499.x · DOI · Paper page
  96. Chernyshev, 2007, Thymidyl biosynthesis enzymes as antibiotic targets, Appl. Microbiol. Biotechnol., 74, 282, 10.1007/s00253-006-0763-1 · DOI
  97. Hampele, 1997, Structure and function of the dihydropteroate synthase from staphylococcus aureus, J. Mol. Biol., 268, 21, 10.1006/jmbi.1997.0944 · DOI · Paper page
  98. Kompis, 2005, DNA and RNA Synthesis: Antifolates, Chem. Rev., 105, 593, 10.1021/cr0301144 · DOI · Paper page
  99. Woods, D.D. (1940). The Relation of p-aminobenzoic Acid to the Mechanism of the Action of Sulphanilamide, Wiley-Blackwell.
  100. Koch, 2003, Bacterial Wall as Target for Attack, Clin. Microbiol. Rev., 16, 673, 10.1128/CMR.16.4.673-687.2003 · DOI · Paper page
  101. Jiang, 2010, Morphology, Growth, and Size Limit of Bacterial Cells, Phys. Rev. Lett., 105, 028101, 10.1103/PhysRevLett.105.028101 · DOI
  102. Cabeen, 2005, Bacterial cell shape, Nat. Rev. Microbiol., 3, 601, 10.1038/nrmicro1205 · DOI · Paper page
  103. Walter, A., and Mayer, C. (2019). Peptidoglycan Structure, Biosynthesis, and Dynamics During Bacterial Growth. Extracellular Sugar-Based Biopolymers Matrices, Springer. · DOI
  104. Burns, 2020, The architecture of the Gram-positive bacterial cell wall, Nature, 582, 294, 10.1038/s41586-020-2236-6 · DOI · Paper page
  105. Schleifer, 1972, Peptidoglycan types of bacterial cell walls and their taxonomic implications, Bacteriol. Rev., 36, 407, 10.1128/br.36.4.407-477.1972 · DOI · Paper page
  106. Boneca, 2000, Characterization of Staphylococcus aureus Cell Wall Glycan Strands, Evidence for a New β-N-Acetylglucosaminidase Activity, J. Biol. Chem., 275, 9910, 10.1074/jbc.275.14.9910 · doi:10.1074/jbc.275.14.9910
  107. Egan, 2020, Regulation of peptidoglycan synthesis and remodelling, Nat. Rev. Microbiol., 18, 446, 10.1038/s41579-020-0366-3 · DOI · Paper page
  108. Vollmer, 2010, Architecture of peptidoglycan: More data and more models, Trends Microbiol., 18, 59, 10.1016/j.tim.2009.12.004 · DOI · Paper page
  109. Silhavy, 2010, The Bacterial Cell Envelope, Cold Spring Harb. Perspect. Biol., 2, a000414, 10.1101/cshperspect.a000414 · DOI · Paper page
  110. Turner, 2014, Different walls for rods and balls: The diversity of peptidoglycan, Mol. Microbiol., 91, 862, 10.1111/mmi.12513 · DOI · Paper page
  111. Matias, 2006, Native cell wall organization shown by cryo-electron microscopy confirms the existence of a periplasmic space in Staphylococcus aureus, J. Bacteriol., 188, 1011, 10.1128/JB.188.3.1011-1021.2006 · DOI · Paper page
  112. Chang, 1992, Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A, J. Biol. Chem., 267, 11248, 10.1016/S0021-9258(19)49903-1 · DOI · Paper page
  113. Naclerio, 2020, Multiple ways to kill bacteria via inhibiting novel cell wall or membrane targets, Future Med. Chem., 12, 1253, 10.4155/fmc-2020-0046 · DOI
  114. Meroueh, 2006, Three-dimensional structure of the bacterial cell wall peptidoglycan, Proc. Natl. Acad. Sci. USA, 103, 4404, 10.1073/pnas.0510182103 · DOI · Paper page
  115. Fishovitz, 2014, Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus, IUBMB Life, 66, 572, 10.1002/iub.1289 · DOI · Paper page
  116. Bugg, T.D.H. (1999). Bacterial Peptidoglycan Biosynthesis and Its Inhibition. Comprehensive Natural Products Chemistry, Elsevier. · DOI
  117. Otero, 2013, How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function, Proc. Natl. Acad. Sci. USA, 110, 16808, 10.1073/pnas.1300118110 · DOI · Paper page
  118. McCallum, 2010, Regulation of antibiotic resistance in Staphylococcus aureus, Int. J. Med. Microbiol., 300, 118, 10.1016/j.ijmm.2009.08.015 · DOI
  119. Weidenmaier, 2008, Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions, Nat. Rev. Microbiol., 6, 276, 10.1038/nrmicro1861 · DOI · Paper page
  120. Epand, 2016, Molecular mechanisms of membrane targeting antibiotics, Biochim. Biophys. Acta—Biomembr., 1858, 980, 10.1016/j.bbamem.2015.10.018 · DOI · Paper page
  121. Halder, 2015, Alteration of Zeta potential and membrane permeability in bacteria: A study with cationic agents, Springerplus, 4, 672, 10.1186/s40064-015-1476-7 · DOI · Paper page
  122. Kim, 2019, A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant Staphylococcus aureus, Proc. Natl. Acad. Sci. USA, 116, 16529, 10.1073/pnas.1904700116 · DOI · Paper page
  123. Luther, 2018, Advances in macrocyclic peptide-based antibiotics, Bioorg. Med. Chem., 26, 2850, 10.1016/j.bmc.2017.08.006 · DOI
  124. Upert, 2021, Emerging peptide antibiotics with therapeutic potential, Med. Drug Discov., 9, 100078, 10.1016/j.medidd.2020.100078 · DOI
  125. Hurdle, 2011, Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections, Nat. Rev. Microbiol., 9, 62, 10.1038/nrmicro2474 · DOI · Paper page
  126. Teixeira, 2012, Role of lipids in the interaction of antimicrobial peptides with membranes, Prog. Lipid Res., 51, 149, 10.1016/j.plipres.2011.12.005 · DOI · Paper page
  127. Hooper, 1999, Mechanisms of fluoroquinolone resistance, Drug Resist. Updat., 2, 38, 10.1054/drup.1998.0068 · DOI · Paper page
  128. Poehlsgaard, 2005, The bacterial ribosome as a target for antibiotics, Nat. Rev. Microbiol., 3, 870, 10.1038/nrmicro1265 · DOI · Paper page
  129. Steitz, 2008, A structural understanding of the dynamic ribosome machine, Nat. Rev. Mol. Cell Biol., 9, 242, 10.1038/nrm2352 · DOI · Paper page
  130. Wilson, 2003, The Ribosome through the Looking Glass, Angew. Chemie Int. Ed., 42, 3464, 10.1002/anie.200200544 · DOI
  131. Ramakrishnan, 2002, Ribosome Structure and the Mechanism of Translation, Cell, 108, 557, 10.1016/S0092-8674(02)00619-0 · DOI · Paper page
  132. Chellat, 2016, Targeting Antibiotic Resistance, Angew. Chem. Int. Ed., 55, 6600, 10.1002/anie.201506818 · DOI · Paper page
  133. Champney, 2020, Antibiotics targeting bacterial ribosomal subunit biogenesis, J. Antimicrob. Chemother., 75, 787, 10.1093/jac/dkz544 · DOI
  134. Greulich, 2017, Predicting the dynamics of bacterial growth inhibition by ribosome-targeting antibiotics, Phys. Biol., 14, 065005, 10.1088/1478-3975/aa8001 · DOI
  135. McCoy, 2011, Antibiotics that target protein synthesis, Wiley Interdiscip. Rev. RNA, 2, 209, 10.1002/wrna.60 · DOI
  136. Stokes, 2015, Chemical modulators of ribosome biogenesis as biological probes, Nat. Chem. Biol., 11, 924, 10.1038/nchembio.1957 · DOI
  137. Stokes, 2014, Discovery of a small molecule that inhibits bacterial ribosome biogenesis, Elife, 3, e03574, 10.7554/eLife.03574 · DOI
  138. Becker, 2013, Aminoglycoside Antibiotics in the 21st Century, ACS Chem. Biol., 8, 105, 10.1021/cb3005116 · DOI · Paper page
  139. Davies, 1968, Misreading of Ribonucleic Acid Code Words Induced by Aminoglycoside Antibiotics, J. Biol. Chem., 243, 3312, 10.1016/S0021-9258(18)93308-9 · DOI · Paper page
  140. Ida, 2002, Antagonism between Aminoglycosides and β-Lactams in a Methicillin-Resistant Staphylococcus aureus Isolate Involves Induction of an Aminoglycoside-Modifying Enzyme, Antimicrob. Agents Chemother., 46, 1516, 10.1128/AAC.46.5.1516-1521.2002 · DOI · Paper page
  141. Cordeiro, 2001, In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitals, Braz. J. Infect. Dis., 5, 130, 10.1590/S1413-86702001000300005 · doi:10.1590/s1413-86702001000300005
  142. Shigemura, 2013, Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011, J. Antibiot., 66, 273, 10.1038/ja.2013.14 · doi:10.1038/ja.2013.14
  143. Bermingham, 2002, The folic acid biosynthesis pathway in bacteria: Evaluation of potential for antibacterial drug discovery, BioEssays, 24, 637, 10.1002/bies.10114 · DOI · Paper page
  144. Santos, 2018, Folate biosynthesis pathway: Mechanisms and insights into drug design for infectious diseases, Future Med. Chem., 10, 935, 10.4155/fmc-2017-0168 · DOI
  145. Fernández-Villa, D., Aguilar, M.R., and Rojo, L. (2019). Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications. Int. J. Mol. Sci., 20. · DOI · Paper page
  146. Schweitzer, 1990, Dihydrofolate reductase as a therapeutic target, FASEB J., 4, 2441, 10.1096/fasebj.4.8.2185970 · doi:10.1096/fasebj.4.8.2185970
  147. Dale, 1997, A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance 1 1 Edited by T.Richmond, J. Mol. Biol., 266, 23, 10.1006/jmbi.1996.0770 · DOI · Paper page
  148. Rouch, 1989, Trimethoprim resistance transposon Tn4003 from Staphylococcus aureus encodes genes for a dihydrofolate reductase and thymidylate synthetase flanked by three copies of IS257, Mol. Microbiol., 3, 161, 10.1111/j.1365-2958.1989.tb01805.x · DOI · Paper page
  149. Kadlec, 2009, Novel ABC Transporter Gene, vga(C), Located on a Multiresistance Plasmid from a Porcine Methicillin-Resistant Staphylococcus aureus ST398 Strain, Antimicrob. Agents Chemother., 53, 3589, 10.1128/AAC.00570-09 · DOI
  150. Perreten, 2010, Clonal spread of methicillin-resistant Staphylococcus pseudintermedius in Europe and North America: An international multicentre study, J. Antimicrob. Chemother., 65, 1145, 10.1093/jac/dkq078 · DOI · Paper page
  151. Nurjadi, 2015, Predominance of dfrG as determinant of trimethoprim resistance in imported Staphylococcus aureus, Clin. Microbiol. Infect., 21, 1095.e5, 10.1016/j.cmi.2015.08.021 · DOI
  152. Paul, 2015, Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: Randomised controlled trial, BMJ, 350, h2219, 10.1136/bmj.h2219 · DOI
  153. Elwell, 1986, In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 29, 1092, 10.1128/AAC.29.6.1092 · DOI
  154. Frei, 2010, Trimethoprim-Sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections, J. Am. Board Fam. Med., 23, 714, 10.3122/jabfm.2010.06.090270 · DOI
  155. Kalkut, 1998, Sulfonamides and Trimethoprim, Cancer Investig., 16, 612, 10.3109/07357909809032892 · doi:10.3109/07357909809032892
  156. Khamash, 2019, Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric Staphylococcus aureus Infections, J. Pediatric Infect. Dis. Soc., 8, 351, 10.1093/jpids/piy062 · DOI
  157. Acree, 2017, S. aureus infections in chicago, 2006–2014: Increase in CA MSSA and decrease in MRSA incidence, Infect. Control. Hosp. Epidemiol., 38, 1226, 10.1017/ice.2017.177 · DOI
  158. Harris, 2018, Investigation of trimethoprim/sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant Staphylococcus aureus clone reveals discrepant resistance reporting, Clin. Microbiol. Infect., 24, 1027, 10.1016/j.cmi.2018.04.020 · DOI
  159. Xia, 2010, The wall teichoic acid and lipoteichoic acid polymers of Staphylococcus aureus, Int. J. Med. Microbiol., 300, 148, 10.1016/j.ijmm.2009.10.001 · DOI · Paper page
  160. Deininger, 2003, Definition of Structural Prerequisites for Lipoteichoic Acid-Inducible Cytokine Induction by Synthetic Derivatives, J. Immunol., 170, 4134, 10.4049/jimmunol.170.8.4134 · DOI
  161. Percy, 2014, Lipoteichoic Acid Synthesis and Function in Gram-Positive Bacteria, Annu. Rev. Microbiol., 68, 81, 10.1146/annurev-micro-091213-112949 · DOI · Paper page
  162. Brown, 2013, Wall Teichoic Acids of Gram-Positive Bacteria, Annu. Rev. Microbiol., 67, 313, 10.1146/annurev-micro-092412-155620 · DOI · Paper page
  163. Neuhaus, 2003, A Continuum of Anionic Charge: Structures and Functions of d-Alanyl-Teichoic Acids in Gram-Positive Bacteria, Microbiol. Mol. Biol. Rev., 67, 686, 10.1128/MMBR.67.4.686-723.2003 · DOI · Paper page
  164. Peschel, 1999, Inactivation of the dlt Operon inStaphylococcus aureus Confers Sensitivity to Defensins, Protegrins, and Other Antimicrobial Peptides, J. Biol. Chem., 274, 8405, 10.1074/jbc.274.13.8405 · DOI · Paper page
  165. Peschel, 2000, The d-Alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes, Antimicrob. Agents Chemother., 44, 2845, 10.1128/AAC.44.10.2845-2847.2000 · DOI · Paper page
  166. Atilano, 2010, Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus, Proc. Natl. Acad. Sci. USA, 107, 18991, 10.1073/pnas.1004304107 · DOI · Paper page
  167. Halfmann, 2006, A Functional dlt Operon, Encoding Proteins Required for Incorporation of d-Alanine in Teichoic Acids in Gram-Positive Bacteria, Confers Resistance to Cationic Antimicrobial Peptides in Streptococcus pneumoniae, J. Bacteriol., 188, 5797, 10.1128/JB.00336-06 · DOI · Paper page
  168. Mechler, 2016, Daptomycin Tolerance in the Staphylococcus aureus pitA6 Mutant Is Due to Upregulation of the dlt Operon, Antimicrob. Agents Chemother., 60, 2684, 10.1128/AAC.03022-15 · DOI
  169. Peschel, 2020, Wall Teichoic Acid in Staphylococcus aureus Host Interaction, Trends Microbiol., 28, 985, 10.1016/j.tim.2020.05.017 · DOI
  170. Kho, 2018, Salt-Induced Stress Stimulates a Lipoteichoic Acid-Specific Three-Component Glycosylation System in Staphylococcus aureus, J. Bacteriol., 200, e00017-18, 10.1128/JB.00017-18 · DOI
  171. Winstel, 2014, Biosynthesis of the Unique Wall Teichoic Acid of Staphylococcus aureus Lineage ST395, MBio, 5, e000869-14, 10.1128/mBio.00869-14 · DOI
  172. Swoboda, 2009, Wall Teichoic Acid Function, Biosynthesis, and Inhibition, ChemBioChem, 11, 35, 10.1002/cbic.200900557 · DOI · Paper page
  173. Simanski, 2013, Staphylococcus aureus subverts cutaneous defense by d -alanylation of teichoic acids, Exp. Dermatol., 22, 294, 10.1111/exd.12114 · DOI
  174. Ernst, 2009, The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion, PLoS Pathog., 5, e1000660, 10.1371/journal.ppat.1000660 · DOI · Paper page
  175. Schlag, 2010, Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl, Mol. Microbiol., 75, 864, 10.1111/j.1365-2958.2009.07007.x · DOI · Paper page
  176. Sadaka, 2014, Compound-gene interaction mapping reveals distinct roles for Staphylococcus aureus teichoic acids, Proc. Natl. Acad. Sci. USA, 111, 12510, 10.1073/pnas.1404099111 · DOI
  177. Campbell, 2011, Synthetic Lethal Compound Combinations Reveal a Fundamental Connection between Wall Teichoic Acid and Peptidoglycan Biosyntheses in Staphylococcus aureus, ACS Chem. Biol., 6, 106, 10.1021/cb100269f · DOI · Paper page
  178. Farha, 2013, Inhibition of WTA Synthesis Blocks the Cooperative Action of PBPs and Sensitizes MRSA to β-Lactams, ACS Chem. Biol., 8, 226, 10.1021/cb300413m · DOI · Paper page
  179. Campbell, 2012, An Antibiotic That Inhibits a Late Step in Wall Teichoic Acid Biosynthesis Induces the Cell Wall Stress Stimulon in Staphylococcus aureus, Antimicrob. Agents Chemother., 56, 1810, 10.1128/AAC.05938-11 · DOI
  180. Schirner, 2009, Distinct and essential morphogenic functions for wall- and lipo-teichoic acids in Bacillus subtilis, EMBO J., 28, 830, 10.1038/emboj.2009.25 · DOI · Paper page
  181. Oku, 2009, Pleiotropic Roles of Polyglycerolphosphate Synthase of Lipoteichoic Acid in Growth of Staphylococcus aureus Cells, J. Bacteriol., 191, 141, 10.1128/JB.01221-08 · DOI · Paper page
  182. Ling, 2009, Aminoacyl-tRNA Synthesis and Translational Quality Control, Annu. Rev. Microbiol., 63, 61, 10.1146/annurev.micro.091208.073210 · DOI · Paper page
  183. Schimmel, 2001, Aminoacyl-tRNA synthetases: Potential markers of genetic code development, Trends Biochem. Sci., 26, 591, 10.1016/S0968-0004(01)01932-6 · DOI
  184. Ibba, 2000, Aminoacyl-tRNA Synthesis, Annu. Rev. Biochem., 69, 617, 10.1146/annurev.biochem.69.1.617 · DOI · Paper page
  185. Eriani, 1990, Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs, Nature, 347, 203, 10.1038/347203a0 · DOI · Paper page
  186. Cassels, 1995, Occurrence of the regulatory nucleotides ppGpp and pppGpp following induction of the stringent response in staphylococci, J. Bacteriol., 177, 5161, 10.1128/jb.177.17.5161-5165.1995 · DOI
  187. Cusack, 1997, Aminoacyl-tRNA synthetases, Curr. Opin. Struct. Biol., 7, 881, 10.1016/S0959-440X(97)80161-3 · DOI · Paper page
  188. Elbaramawi, 2017, Exploring the binding sites of Staphylococcus aureus phenylalanine tRNA synthetase: A homology model approach, J. Mol. Graph. Model., 73, 36, 10.1016/j.jmgm.2017.02.002 · doi:10.1016/j.jmgm.2017.02.002
  189. Sutherland, 1985, Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use, Antimicrob. Agents Chemother., 27, 495, 10.1128/AAC.27.4.495 · doi:10.1128/aac.27.4.495
  190. Hurdle, 2005, Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents, Antimicrob. Agents Chemother., 49, 4821, 10.1128/AAC.49.12.4821-4833.2005 · DOI · Paper page
  191. Breukink, 2006, Lipid II as a target for antibiotics, Nat. Rev. Drug Discov., 5, 321, 10.1038/nrd2004 · DOI · Paper page
  192. Schneider, 2010, An oldie but a goodie—Cell wall biosynthesis as antibiotic target pathway, Int. J. Med. Microbiol., 300, 161, 10.1016/j.ijmm.2009.10.005 · DOI · Paper page
  193. 2007, Lipid Intermediates in the Biosynthesis of Bacterial Peptidoglycan, Microbiol. Mol. Biol. Rev., 71, 620, 10.1128/MMBR.00016-07 · DOI · Paper page
  194. Mikkelsen, 2021, The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids, Int. J. Antimicrob. Agents, 57, 106283, 10.1016/j.ijantimicag.2021.106283 · DOI
  195. Jousselin, 2016, The Staphylococcus aureus Chaperone PrsA Is a New Auxiliary Factor of Oxacillin Resistance Affecting Penicillin-Binding Protein 2A, Antimicrob. Agents Chemother., 60, 1656, 10.1128/AAC.02333-15 · DOI
  196. Gardete, 2004, Role of murE in the Expression of β-Lactam Antibiotic Resistance in Staphylococcus aureus, J. Bacteriol., 186, 1705, 10.1128/JB.186.6.1705-1713.2004 · doi:10.1128/jb.186.6.1705-1713.2004
  197. Memmi, 2008, Staphylococcus aureus PBP4 Is Essential for β-Lactam Resistance in Community-Acquired Methicillin-Resistant Strains, Antimicrob. Agents Chemother., 52, 3955, 10.1128/AAC.00049-08 · DOI · Paper page
  198. Rohrer, 1999, The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation, Proc. Natl. Acad. Sci. USA, 96, 9351, 10.1073/pnas.96.16.9351 · DOI
  199. Brown, 2012, Methicillin resistance in Staphylococcus aureus requires glycosylated wall teichoic acids, Proc. Natl. Acad. Sci. USA, 109, 18909, 10.1073/pnas.1209126109 · DOI · Paper page
  200. Lee, 2011, Antagonism of Chemical Genetic Interaction Networks Resensitize MRSA to β-Lactam Antibiotics, Chem. Biol., 18, 1379, 10.1016/j.chembiol.2011.08.015 · DOI

200 of 256 shown

Cited by

See all 134

Metadata

Authors
Lade, H., & Kim, J.-S.
Venue
Antibiotics
Publisher
MDPI AG
Published
2021-04-07
Volume
10
Issue
4
Pages
398
ISSN
2079-6382
DOI
10.3390/antibiotics10040398
Cited by
134
References
15
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Research Foundation of Korea (2017M3A9E4077232)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus aureus. https://app.cochat.ai/papers/10.3390/antibiotics10040398
The paper
Lade, H., & Kim, J.-S. (2021). Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus aureus. Antibiotics. https://doi.org/10.3390/antibiotics10040398

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.